Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X.
Annalaura BraiStefania RonziniValentina RivaLorenzo BottaClaudio ZamperiniMatteo BorginiClaudia Immacolata TrivisaniAnna GarbelliCarla PennisiAdele BoccutoFrancesco SaladiniMaurizio ZazziGiovanni MagaMaurizio BottaPublished in: Molecules (Basel, Switzerland) (2019)
The human ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against both infectious diseases and cancer. Herein, a new family of DDX3X inhibitors was designed, synthesized, and tested for its inhibitory action on the ATPase activity of the enzyme. The potential use of the most promising derivatives it has been investigated by evaluating their anti-HIV-1 effects, revealing inhibitory activities in the low micromolar range. A preliminary ADME analysis demonstrated high metabolic stability and good aqueous solubility. The promising biological profile, together with the suitable in vitro pharmacokinetic properties, make these novel compounds a very good starting point for further development.
Keyphrases
- infectious diseases
- endothelial cells
- antiretroviral therapy
- hiv positive
- papillary thyroid
- human immunodeficiency virus
- hiv infected
- hepatitis c virus
- transcription factor
- hiv aids
- squamous cell
- induced pluripotent stem cells
- binding protein
- squamous cell carcinoma
- atomic force microscopy
- risk assessment
- high resolution
- pluripotent stem cells
- nucleic acid
- lymph node metastasis